Growth in the Cost of Biologics in Medicare Beneficiaries, 2017 to 2019.
作者信息
Laborada Jennifer, Shin Leah, Lee Claudia, Shahsavari Shahin, Egeberg Alexander, Wu Jashin J
机构信息
Drs. Laborada and Lee are with the University of California Riverside School of Medicine in Riverside, California.
Dr. Shin is with Loma Linda University School of Medicine in Loma Linda, California.
出版信息
J Clin Aesthet Dermatol. 2024 Jul;17(7):17-18.
Abstract
摘要
相似文献
1
Growth in the Cost of Biologics in Medicare Beneficiaries, 2017 to 2019.2017年至2019年医疗保险受益人生物制剂成本的增长情况
J Clin Aesthet Dermatol. 2024 Jul;17(7):17-18.
2
Psoriasis drugs in the medicare population: dermatologists' spending and prescription patterns.医疗保险人群中的银屑病药物：皮肤科医生的支出和处方模式。
J Dermatolog Treat. 2022 May;33(3):1758-1761. doi: 10.1080/09546634.2020.1864265. Epub 2021 Jan 20.
3
Medicare and medicaid spending trends for immunomodulators prescribed for dermatologic conditions.医疗保险和医疗补助对治疗皮肤病的免疫调节剂的支出趋势。
J Dermatolog Treat. 2022 Feb;33(1):575-579. doi: 10.1080/09546634.2020.1762842. Epub 2020 May 13.
4
Adoption of newly FDA-approved targeted immunomodulatory therapies by dermatologists: a cross-sectional analysis of Medicare Part D claims from 2013 to 2018.皮肤科医生对美国食品药品监督管理局（FDA）新批准的靶向免疫调节疗法的采用情况：对2013年至2018年医疗保险D部分索赔的横断面分析
Arch Dermatol Res. 2023 Apr;315(3):673-676. doi: 10.1007/s00403-022-02422-3. Epub 2022 Oct 25.
5
Trends In Medicare Fee-For-Service Spending Growth For Dual-Eligible Beneficiaries, 2007-15.2007-2015 年，双重资格受益人的医疗保险按服务收费支出增长趋势。
Health Aff (Millwood). 2018 Aug;37(8):1265-1273. doi: 10.1377/hlthaff.2018.0143.
6
Association of Pioneer Accountable Care Organizations vs traditional Medicare fee for service with spending, utilization, and patient experience.先驱责任医疗组织与传统 Medicare 按服务收费制在支出、利用和患者体验方面的关联。
JAMA. 2015 Jun 2;313(21):2152-61. doi: 10.1001/jama.2015.4930.
7
Spending on and Use of Clinician-Administered Drugs in Medicare.医疗保险中临床医生管理药物的支出和使用。
JAMA Health Forum. 2023 Sep 1;4(9):e232941. doi: 10.1001/jamahealthforum.2023.2941.
8
Supplemental coverage associated with more rapid spending growth for Medicare beneficiaries.补充覆盖范围与医疗保险受益人的支出增长速度加快有关。
Health Aff (Millwood). 2013 May;32(5):873-81. doi: 10.1377/hlthaff.2012.1230.
9
Association of Medicare Advantage Penetration With Per Capita Spending, Emergency Department Visits, and Readmission Rates Among Fee-for-Service Medicare Beneficiaries With High Comorbidity Burden.医疗保险优势计划渗透率与高合并症负担的医疗保险服务收费受益人的人均支出、急诊就诊率和再入院率之间的关联。
Med Care Res Rev. 2021 Dec;78(6):703-712. doi: 10.1177/1077558720952582. Epub 2020 Aug 26.
10
Out-of-pocket health spending by poor and near-poor elderly Medicare beneficiaries.贫困和接近贫困的老年医疗保险受益人的自付医疗费用。
Health Serv Res. 1999 Apr;34(1 Pt 2):241-54.
本文引用的文献
1
Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open-label CADMUS Jr study.乌司奴单抗治疗儿童患者（≥6至<12岁）中重度斑块状银屑病：开放标签CADMUS Jr研究的疗效、安全性、药代动力学及生物标志物结果
Br J Dermatol. 2020 Oct;183(4):664-672. doi: 10.1111/bjd.19018. Epub 2020 May 10.
2
Growth in the cost of biologics in Medicare beneficiaries, 2013 to 2016.2013年至2016年医疗保险受益人使用生物制剂的费用增长情况。
J Am Acad Dermatol. 2019 Jan;80(1):281-282. doi: 10.1016/j.jaad.2018.08.004. Epub 2018 Aug 14.
3
Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis.优特克单抗治疗银屑病和银屑病关节炎。
Rheumatol Ther. 2015 Jun;2(1):1-16. doi: 10.1007/s40744-015-0010-2. Epub 2015 Mar 17.
Zotero 插件